HIV-1 Drug Resistance Genotyping View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2000-11

AUTHORS

Carine Chaix-Couturier, Christopher Holtzer, Kathryn A. Phillips, Isabelle Durand-Zaleski, John Stansell

ABSTRACT

The development of mutations associated with resistance to antiretroviral therapy (ART) has been shown to be a major cause of treatment failure in patients infected with HIV-1. These resistance mutations can be assessed by a genotyping test that probes for specific mutations within the HIV genome or sequences specific genes, at a cost $US500/test (2000 prices). The stated goal of HIV-1 genotyping is to target HIV therapy effectively. This, as shown in the preliminary research, should result in better clinical outcomes and a lower incidence of virological failure and may be associated with lower costs of treatment. Failure of ART may result in an increase in costs of at least $US250 per patient per month, as assessed in 1 study, with costs rising further as patients experience multiple virological failures. Therefore, there is an economic as well as a therapeutic premium on the prevention of ART failure.The actual economic cost of genotyping has been preliminarily explored in the context of the antiretro VIRal ADAPTation (VIRADAPT) trial, which found no significant difference in the 1-year treatment cost of patients with and without genotyping. There is some evidence of cost neutrality or savings with genotypic testing but it needs to be further explored within the context of carefully framed prospective trials. More... »

PAGES

425-433

Identifiers

URI

http://scigraph.springernature.com/pub.10.2165/00019053-200018050-00002

DOI

http://dx.doi.org/10.2165/00019053-200018050-00002

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1006547897

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/11151396


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anti-HIV Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Resistance, Microbial", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Genetic Techniques", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Genotype", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "HIV Infections", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "HIV-1", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Randomized Controlled Trials as Topic", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Public Health, Henri Mondor Hospital, AP-HP Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.412116.1", 
          "name": [
            "Public Health, Henri Mondor Hospital, AP-HP Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chaix-Couturier", 
        "givenName": "Carine", 
        "id": "sg:person.0706456771.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0706456771.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Visible Genetics, Evry, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Visible Genetics, Evry, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Holtzer", 
        "givenName": "Christopher", 
        "id": "sg:person.01011726655.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01011726655.09"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Health Economics and Health Services Research, University of California, San Francisco, California, USA", 
          "id": "http://www.grid.ac/institutes/grid.266102.1", 
          "name": [
            "Health Economics and Health Services Research, University of California, San Francisco, California, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Phillips", 
        "givenName": "Kathryn A.", 
        "id": "sg:person.012246046672.66", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012246046672.66"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Public Health, Henri Mondor Hospital, AP-HP Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.412116.1", 
          "name": [
            "Public Health, Henri Mondor Hospital, AP-HP Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Durand-Zaleski", 
        "givenName": "Isabelle", 
        "id": "sg:person.01327533357.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01327533357.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Positive Health Program, San Francisco General Hospital, Associate Professor of Medicine, University of California, San Francisco, California, USA", 
          "id": "http://www.grid.ac/institutes/grid.416732.5", 
          "name": [
            "Positive Health Program, San Francisco General Hospital, Associate Professor of Medicine, University of California, San Francisco, California, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Stansell", 
        "givenName": "John", 
        "id": "sg:person.0757362427.84", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0757362427.84"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1023/a:1011949221202", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051157100", 
          "https://doi.org/10.1023/a:1011949221202"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/373123a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014949926", 
          "https://doi.org/10.1038/373123a0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00019053-199814060-00005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046426436", 
          "https://doi.org/10.2165/00019053-199814060-00005"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00019053-199916030-00007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041358935", 
          "https://doi.org/10.2165/00019053-199916030-00007"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00019053-199813030-00007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043205062", 
          "https://doi.org/10.2165/00019053-199813030-00007"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2000-11", 
    "datePublishedReg": "2000-11-01", 
    "description": "The development of mutations associated with resistance to antiretroviral therapy (ART) has been shown to be a major cause of treatment failure in patients infected with HIV-1. These resistance mutations can be assessed by a genotyping test that probes for specific mutations within the HIV genome or sequences specific genes, at a cost $US500/test (2000 prices). The stated goal of HIV-1 genotyping is to target HIV therapy effectively. This, as shown in the preliminary research, should result in better clinical outcomes and a lower incidence of virological failure and may be associated with lower costs of treatment. Failure of ART may result in an increase in costs of at least $US250 per patient per month, as assessed in 1 study, with costs rising further as patients experience multiple virological failures. Therefore, there is an economic as well as a therapeutic premium on the prevention of ART failure.The actual economic cost of genotyping has been preliminarily explored in the context of the antiretro VIRal ADAPTation (VIRADAPT) trial, which found no significant difference in the 1-year treatment cost of patients with and without genotyping. There is some evidence of cost neutrality or savings with genotypic testing but it needs to be further explored within the context of carefully framed prospective trials.", 
    "genre": "article", 
    "id": "sg:pub.10.2165/00019053-200018050-00002", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1102812", 
        "issn": [
          "1170-7690", 
          "1179-2027"
        ], 
        "name": "PharmacoEconomics", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "5", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "18"
      }
    ], 
    "keywords": [
      "antiretroviral therapy", 
      "virological failure", 
      "HIV-1 drug resistance genotyping", 
      "failure of ART", 
      "multiple virological failures", 
      "drug resistance genotyping", 
      "better clinical outcomes", 
      "HIV-1 genotyping", 
      "development of mutations", 
      "prospective trial", 
      "treatment failure", 
      "clinical outcomes", 
      "ART failure", 
      "resistance genotyping", 
      "HIV therapy", 
      "lower incidence", 
      "genotypic testing", 
      "HIV-1", 
      "patients", 
      "resistance mutations", 
      "HIV genome", 
      "major cause", 
      "treatment costs", 
      "cost neutrality", 
      "significant differences", 
      "therapy", 
      "actual economic costs", 
      "trials", 
      "specific mutations", 
      "genotyping", 
      "failure", 
      "adaptation trials", 
      "mutations", 
      "sequence-specific gene", 
      "specific genes", 
      "incidence", 
      "months", 
      "prevention", 
      "outcomes", 
      "economic costs", 
      "treatment", 
      "cause", 
      "test", 
      "evidence", 
      "differences", 
      "testing", 
      "genes", 
      "study", 
      "increase", 
      "preliminary research", 
      "resistance", 
      "development", 
      "cost", 
      "goal", 
      "research", 
      "stated goal", 
      "probe", 
      "context", 
      "genome", 
      "low cost", 
      "savings", 
      "premium", 
      "neutrality"
    ], 
    "name": "HIV-1 Drug Resistance Genotyping", 
    "pagination": "425-433", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1006547897"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.2165/00019053-200018050-00002"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "11151396"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.2165/00019053-200018050-00002", 
      "https://app.dimensions.ai/details/publication/pub.1006547897"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-11-24T20:49", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/article/article_319.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.2165/00019053-200018050-00002"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.2165/00019053-200018050-00002'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.2165/00019053-200018050-00002'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.2165/00019053-200018050-00002'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.2165/00019053-200018050-00002'


 

This table displays all metadata directly associated to this object as RDF triples.

213 TRIPLES      21 PREDICATES      102 URIs      89 LITERALS      15 BLANK NODES

Subject Predicate Object
1 sg:pub.10.2165/00019053-200018050-00002 schema:about N0269ba23277849f5b53eb4aedd397dd4
2 N187cdc7db46f47a7afb169031d834a36
3 N2449e4f1cb894ea08c4ee1f74c4ba802
4 N3fd3cac1d599469e99d65ccd099dfc67
5 N50e61aadb0a3452f9682574f175abb64
6 N7bccf94d48e740459cf0c4e7b85fec4c
7 Nae0805fa700547faae425ceb378a011c
8 Ne20cb8365ab04a12adf2858c8713c17c
9 anzsrc-for:11
10 anzsrc-for:1103
11 schema:author Nfc30f82322b9445f94152008be52661d
12 schema:citation sg:pub.10.1023/a:1011949221202
13 sg:pub.10.1038/373123a0
14 sg:pub.10.2165/00019053-199813030-00007
15 sg:pub.10.2165/00019053-199814060-00005
16 sg:pub.10.2165/00019053-199916030-00007
17 schema:datePublished 2000-11
18 schema:datePublishedReg 2000-11-01
19 schema:description The development of mutations associated with resistance to antiretroviral therapy (ART) has been shown to be a major cause of treatment failure in patients infected with HIV-1. These resistance mutations can be assessed by a genotyping test that probes for specific mutations within the HIV genome or sequences specific genes, at a cost $US500/test (2000 prices). The stated goal of HIV-1 genotyping is to target HIV therapy effectively. This, as shown in the preliminary research, should result in better clinical outcomes and a lower incidence of virological failure and may be associated with lower costs of treatment. Failure of ART may result in an increase in costs of at least $US250 per patient per month, as assessed in 1 study, with costs rising further as patients experience multiple virological failures. Therefore, there is an economic as well as a therapeutic premium on the prevention of ART failure.The actual economic cost of genotyping has been preliminarily explored in the context of the antiretro VIRal ADAPTation (VIRADAPT) trial, which found no significant difference in the 1-year treatment cost of patients with and without genotyping. There is some evidence of cost neutrality or savings with genotypic testing but it needs to be further explored within the context of carefully framed prospective trials.
20 schema:genre article
21 schema:isAccessibleForFree false
22 schema:isPartOf N34278f172ce64f45a54a5210962b92de
23 Nd62555210da64439866d944f7a8120bc
24 sg:journal.1102812
25 schema:keywords ART failure
26 HIV genome
27 HIV therapy
28 HIV-1
29 HIV-1 drug resistance genotyping
30 HIV-1 genotyping
31 actual economic costs
32 adaptation trials
33 antiretroviral therapy
34 better clinical outcomes
35 cause
36 clinical outcomes
37 context
38 cost
39 cost neutrality
40 development
41 development of mutations
42 differences
43 drug resistance genotyping
44 economic costs
45 evidence
46 failure
47 failure of ART
48 genes
49 genome
50 genotypic testing
51 genotyping
52 goal
53 incidence
54 increase
55 low cost
56 lower incidence
57 major cause
58 months
59 multiple virological failures
60 mutations
61 neutrality
62 outcomes
63 patients
64 preliminary research
65 premium
66 prevention
67 probe
68 prospective trial
69 research
70 resistance
71 resistance genotyping
72 resistance mutations
73 savings
74 sequence-specific gene
75 significant differences
76 specific genes
77 specific mutations
78 stated goal
79 study
80 test
81 testing
82 therapy
83 treatment
84 treatment costs
85 treatment failure
86 trials
87 virological failure
88 schema:name HIV-1 Drug Resistance Genotyping
89 schema:pagination 425-433
90 schema:productId N3da55fdf83184257b988e10c038624cd
91 N8198c5bc2971408998378016641cc1e4
92 Nec53bd52b47f45f189669346c73ddffa
93 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006547897
94 https://doi.org/10.2165/00019053-200018050-00002
95 schema:sdDatePublished 2022-11-24T20:49
96 schema:sdLicense https://scigraph.springernature.com/explorer/license/
97 schema:sdPublisher N7d42f31e833c4d729c388f760e5ba8de
98 schema:url https://doi.org/10.2165/00019053-200018050-00002
99 sgo:license sg:explorer/license/
100 sgo:sdDataset articles
101 rdf:type schema:ScholarlyArticle
102 N0269ba23277849f5b53eb4aedd397dd4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Genotype
104 rdf:type schema:DefinedTerm
105 N134689ead98a47cc8f56adf120b1cd57 rdf:first sg:person.01011726655.09
106 rdf:rest N2eb1902bc13a48f8b563fd208683e045
107 N187cdc7db46f47a7afb169031d834a36 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Anti-HIV Agents
109 rdf:type schema:DefinedTerm
110 N2449e4f1cb894ea08c4ee1f74c4ba802 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Drug Resistance, Microbial
112 rdf:type schema:DefinedTerm
113 N2eb1902bc13a48f8b563fd208683e045 rdf:first sg:person.012246046672.66
114 rdf:rest Ne454838caebc491fa600afcc1fc00649
115 N34278f172ce64f45a54a5210962b92de schema:issueNumber 5
116 rdf:type schema:PublicationIssue
117 N3da55fdf83184257b988e10c038624cd schema:name doi
118 schema:value 10.2165/00019053-200018050-00002
119 rdf:type schema:PropertyValue
120 N3fd3cac1d599469e99d65ccd099dfc67 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name HIV Infections
122 rdf:type schema:DefinedTerm
123 N50e61aadb0a3452f9682574f175abb64 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Humans
125 rdf:type schema:DefinedTerm
126 N663313bfecff4a37a902b9e16b089f12 rdf:first sg:person.0757362427.84
127 rdf:rest rdf:nil
128 N7bccf94d48e740459cf0c4e7b85fec4c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name HIV-1
130 rdf:type schema:DefinedTerm
131 N7d42f31e833c4d729c388f760e5ba8de schema:name Springer Nature - SN SciGraph project
132 rdf:type schema:Organization
133 N8198c5bc2971408998378016641cc1e4 schema:name pubmed_id
134 schema:value 11151396
135 rdf:type schema:PropertyValue
136 Nae0805fa700547faae425ceb378a011c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Randomized Controlled Trials as Topic
138 rdf:type schema:DefinedTerm
139 Nd62555210da64439866d944f7a8120bc schema:volumeNumber 18
140 rdf:type schema:PublicationVolume
141 Ne20cb8365ab04a12adf2858c8713c17c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Genetic Techniques
143 rdf:type schema:DefinedTerm
144 Ne454838caebc491fa600afcc1fc00649 rdf:first sg:person.01327533357.46
145 rdf:rest N663313bfecff4a37a902b9e16b089f12
146 Nec53bd52b47f45f189669346c73ddffa schema:name dimensions_id
147 schema:value pub.1006547897
148 rdf:type schema:PropertyValue
149 Nfc30f82322b9445f94152008be52661d rdf:first sg:person.0706456771.29
150 rdf:rest N134689ead98a47cc8f56adf120b1cd57
151 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
152 schema:name Medical and Health Sciences
153 rdf:type schema:DefinedTerm
154 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
155 schema:name Clinical Sciences
156 rdf:type schema:DefinedTerm
157 sg:journal.1102812 schema:issn 1170-7690
158 1179-2027
159 schema:name PharmacoEconomics
160 schema:publisher Springer Nature
161 rdf:type schema:Periodical
162 sg:person.01011726655.09 schema:affiliation grid-institutes:None
163 schema:familyName Holtzer
164 schema:givenName Christopher
165 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01011726655.09
166 rdf:type schema:Person
167 sg:person.012246046672.66 schema:affiliation grid-institutes:grid.266102.1
168 schema:familyName Phillips
169 schema:givenName Kathryn A.
170 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012246046672.66
171 rdf:type schema:Person
172 sg:person.01327533357.46 schema:affiliation grid-institutes:grid.412116.1
173 schema:familyName Durand-Zaleski
174 schema:givenName Isabelle
175 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01327533357.46
176 rdf:type schema:Person
177 sg:person.0706456771.29 schema:affiliation grid-institutes:grid.412116.1
178 schema:familyName Chaix-Couturier
179 schema:givenName Carine
180 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0706456771.29
181 rdf:type schema:Person
182 sg:person.0757362427.84 schema:affiliation grid-institutes:grid.416732.5
183 schema:familyName Stansell
184 schema:givenName John
185 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0757362427.84
186 rdf:type schema:Person
187 sg:pub.10.1023/a:1011949221202 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051157100
188 https://doi.org/10.1023/a:1011949221202
189 rdf:type schema:CreativeWork
190 sg:pub.10.1038/373123a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014949926
191 https://doi.org/10.1038/373123a0
192 rdf:type schema:CreativeWork
193 sg:pub.10.2165/00019053-199813030-00007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043205062
194 https://doi.org/10.2165/00019053-199813030-00007
195 rdf:type schema:CreativeWork
196 sg:pub.10.2165/00019053-199814060-00005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046426436
197 https://doi.org/10.2165/00019053-199814060-00005
198 rdf:type schema:CreativeWork
199 sg:pub.10.2165/00019053-199916030-00007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041358935
200 https://doi.org/10.2165/00019053-199916030-00007
201 rdf:type schema:CreativeWork
202 grid-institutes:None schema:alternateName Visible Genetics, Evry, France
203 schema:name Visible Genetics, Evry, France
204 rdf:type schema:Organization
205 grid-institutes:grid.266102.1 schema:alternateName Health Economics and Health Services Research, University of California, San Francisco, California, USA
206 schema:name Health Economics and Health Services Research, University of California, San Francisco, California, USA
207 rdf:type schema:Organization
208 grid-institutes:grid.412116.1 schema:alternateName Public Health, Henri Mondor Hospital, AP-HP Paris, France
209 schema:name Public Health, Henri Mondor Hospital, AP-HP Paris, France
210 rdf:type schema:Organization
211 grid-institutes:grid.416732.5 schema:alternateName Positive Health Program, San Francisco General Hospital, Associate Professor of Medicine, University of California, San Francisco, California, USA
212 schema:name Positive Health Program, San Francisco General Hospital, Associate Professor of Medicine, University of California, San Francisco, California, USA
213 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...